Journal article
Eligibility and Projected Benefits of Rapid Initiation of Quadruple Therapy for Newly Diagnosed Heart Failure
Abstract
BACKGROUND: U.S. nationwide estimates of the proportion of patients newly diagnosed with heart failure with reduced ejection fraction (HFrEF) eligible for quadruple medical therapy, and the associated benefits of rapid implementation, are not well characterized.
OBJECTIVES: This study sought to characterize the degree to which patients newly diagnosed with HFrEF are eligible for quadruple medical therapy, and the projected benefits of …
Authors
Greene SJ; Ayodele I; Pierce JB; Khan MS; Lewsey SC; Yancy CW; Alhanti B; Van Spall HGC; Allen LA; Fonarow GC
Journal
JACC Heart Failure, Vol. 12, No. 8, pp. 1365–1377
Publisher
Elsevier
Publication Date
August 2024
DOI
10.1016/j.jchf.2024.03.001
ISSN
2213-1779
Fields of Research (FoR)
Sustainable Development Goals (SDG)
Medical Subject Headings (MeSH)
HumansHeart FailureMaleAdrenergic beta-AntagonistsFemaleAgedMineralocorticoid Receptor AntagonistsAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsStroke VolumeDrug Therapy, CombinationUnited StatesSodium-Glucose Transporter 2 InhibitorsRegistriesNeprilysinMiddle AgedHospitalizationAged, 80 and overEligibility Determination